Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Staphylococcus Species Leads the Eskape Infections in Various Hematological Malignancies

Purnima Sravanti Teegavarapu, MD, Mamta Puppala, MSc, Sai Ravi Pingali, MD, Asmita Patel, Ibrahim Ibrahim, MD, Akash Mukherjee, MD, Lawrence Rice, MD, Swaminathan Padmanabhan Iyer, MD

Blood (2015) 126 (23): 4623.

https://doi.org/10.1182/blood.V126.23.4623.4623

Published: 2015

Journal Articles

Leukapheresis Reduces 4-Week Mortality in Leukemia Patient with Hyperleukocytosis-a Retrospective Study from a Tertiary Center

Nan Xinyu, Srivastava Pallavi, Mamta Puppala, MSc, Sai Ravi Pingali, MD, Ibrahim Ibrahim, Lawrence Rice, MD, Alexandria T. Phan, MD, Swaminathan Padmanabhan Iyer, MD

Blood (2015) 126 (23): 3782.

https://doi.org/10.1182/blood.V126.23.3782.3782

Published: 2015

Journal Articles

Systematic Drug Repositioning By Integrating Transcriptome and Historical Clinical Data, Identification of Digoxin As a Novel Drug Reposition Candidate for High-Risk Myelodysplastic Syndromes

Huojun Cao, Zheng Yin, PhD, Shenyi Chen, Timothy Liu, Jiyong Liu, Yaping Hu, Hong Zhao, Lawrence Rice, MD, Swaminathan Padmanabhan Iyer, MD, Stephen Wong

Blood (2015) 126 (23): 4118.

https://doi.org/10.1182/blood.V126.23.4118.4118

Published: 2015

Journal Articles

Mechanistic Role of HEXIM1 Induction in BRD4-Antagonist Mediated Growth Inhibition, Differentiation and in Vivo Lethal Activity Against Human AML Blast Progenitor Cells

Santhana G. T. Devaraj, PhD, Warren Fiskus, PhD, Bhavin Shah, Sunil Sharma, Jun Qi, PhD, Baohua Sun, MD PhD, Saikat Saha, PhD, Swaminathan Padmanabhan Iyer, MD, Youli Zu, MD PhD, James Bradner, MD, Kapil N. Bhalla, MD

Blood (2014) 124 (21): 3534.

https://doi.org/10.1182/blood.V124.21.3534.3534

Published: 2014

Journal Articles

Combined Targeting of β-Catenin and FLT-3 Is Synergistically Lethal Against Cultured and Primary AML Blast Progenitor Cells Expressing FLT3 Internal Tandem Duplication (ITD)

Saikat Saha, PhD, Warren Fiskus, PhD, Sunil Sharma, Bhavin Shah, Anna T Rogojina, Santhana G. T. Devaraj, PhD, Baohua Sun, MD PhD, Christopher Leveque, MD, Youli Zu, MD PhD, Swaminathan Padmanabhan Iyer, MD, Kapil N. Bhalla, MD

Blood (2014) 124 (21): 618.

https://doi.org/10.1182/blood.V124.21.618.618

Published: 2014

Journal Articles

Neighborhood Death Rate: A Big-Data Based Health Informatics Pipeline Helps Identify Factors Impacting Clinical Outcomes and Cost Effectiveness in Acute Myeloid Leukemia Patients

Zheng Yin, Anish S Konde, MB BS, Mamta Puppala, MS, Pallavi Srivastava, Wong Stephen, Lawrence Rice, MD, Swaminathan Padmanabhan Iyer, MD

Blood (2014) 124 (21): 2625.

https://doi.org/10.1182/blood.V124.21.2625.2625

Published: 2014

Journal Articles

Romidepsin Induces Durable Responses in Patients with Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL)

Barbara Pro, MD, Steven M. Horwitz, MD, H. Miles Prince, MB BS (Hons) MDFRACP FRCPA AFRACMA MACD, Francine M. Foss, MD, Lubomir Sokol, MD PhD, Matthew Greenwood, MD FRACP, FRCPA, Dolores Caballero, Franck Morschhauser, MD PhD, Martin Wilhelm, MD, Lauren Pinter-Brown, Prof, MD FACP, Swaminathan Padmanabhan Iyer, MD Dir, Hematological Malignancies, Andrei R. Shustov, MD, Julie Wolfson, MPH, Barbara E Balser, VMD, Bertrand Coiffier, MD PhD Prof

Blood (2014) 124 (21): 1742.

https://doi.org/10.1182/blood.V124.21.1742.1742

Published: 2014

Journal Articles

Superior Pre-Clinical Activity of BET (Bromodomain and Extra terminal) Protein Antagonist Combined with Ibrutinib, Panobinostat or Carfilzomib Against Human Mantle Cell Lymphoma (MCL) Cells

Baohua Sun, MD PhD, Warren Fiskus, PhD, Bhavin Shah, Jun Qi, PhD, Santhana G. T. Devaraj, PhD, Swaminathan Padmanabhan Iyer, MD, Sunil Sharma, James Bradner, MD, Youli Zu, MD PhD, Kapil N. Bhalla, MD

Blood (2014) 124 (21): 918.

https://doi.org/10.1182/blood.V124.21.918.918

Published: 2014

Journal Articles

Combined Therapy With BRD4 Antagonist and JAK Inhibitor Is Synergistically Lethal Against Human Myeloproliferative Neoplasm (MPN) Cells

John A Valenta, M.S., Warren Fiskus, Ph.D, Taghi Manshouri, Ph.D., Sunil Sharma, MD, Jun Qi, PhD, Leasha J Schaub, M.S., Bhavin Shah, Melissa Rodriguez, M.D., Ph.D, Santhana Devaraj, Ph.D, Swaminathan Padmanabhan Iyer, MD, Srdan Verstovsek, MD, PhD, James E Bradner, MD, Kapil N. Bhalla, MD

Blood (2013) 122 (21): 2842.

https://doi.org/10.1182/blood.V122.21.2842.2842

Published: 2013

Journal Articles

A Retrospective Review Of Factor X Levels and Bleeding Risk In Patients With Amyloidosis

Anish S. Konde, MB BS, Charles Camposano, Mushtaq Farah, Puppala Mamta, Wong Solomon, George Carrum, McCarthy John, Kelty R. Baker, MD, Jerry Estep, Arvind Bhimraj, Rammurti Kamble, MD, Lawrence Rice, MD, Swaminathan Padmanabhan Iyer, MD, MB, BS

Blood (2013) 122 (21): 3603.

https://doi.org/10.1182/blood.V122.21.3603.3603

Published: 2013

Journal Articles

Phase 1 Study Of Investigational Agent MLN8237 (Alisertib) + Rituximab ± Vincristine In Patients (Pts) With Relapsed/Refractory (Rel/Ref) Aggressive B-Cell Lymphomas

Kevin R. Kelly, MD, PhD, Daniel O. Persky, MD, Daruka Mahadevan, MD, PhD, Thomas P. Miller, MD, Soham D. Puvvada, MD, Kevin McDonagh, MD, John Hayslip, MD, Steven I. Park, MD, Jia Ruan, MD, PhD, Peter J. Rosen, MD, Swaminathan Padmanabhan Iyer, MD, MB, BS, Alexandra Stefanovic, MD, Bin Zhang, ScD, Xiaofei Zhou, PhD, Claudio Dansky Ullmann, MD, E. Jane Leonard, MSc, Jonathan W. Friedberg, MD

Blood (2013) 122 (21): 3027.

https://doi.org/10.1182/blood.V122.21.3027.3027

Published: 2013

Journal Articles

Combined Therapy With BRD4 Antagonist and FLT3 Inhibitor Exerts Synergistic Activity Against Cultured and Primary AML Blast Progenitors Expressing FLT-ITD

Melissa Rodriguez, M.D., Ph.D, Warren Fiskus, Ph.D, Sunil Sharma, MD, Jun Qi, PhD, John A Valenta, M.S., Leasha J Schaub, M.S., Bhavin Shah, Santhana Devaraj, Ph.D, Swaminathan Padmanabhan Iyer, MD, James E Bradner, MD, Kapil N. Bhalla, MD

Blood (2013) 122 (21): 3821.

https://doi.org/10.1182/blood.V122.21.3821.3821

Published: 2013

Journal Articles

BRD4 Antagonist and Histone Deacetylase Inhibitor: A Novel Synergistic Combination Against Human Acute Myeloid Leukemia (AML) Cells

Warren Fiskus, Ph.D, Sunil Sharma, MD, Jun Qi, PhD, John A Valenta, M.S., Leasha J Schaub, M.S., Bhavin Shah, Karissa Peth, Laxmi U.M.R. Jakkula, PhD, Melissa Rodriguez, M.D., Ph.D, Santhana Devaraj, Ph.D, Swaminathan Padmanabhan Iyer, MD, James E Bradner, MD, Kapil N. Bhalla, MD

Blood (2013) 122 (21): 485.

https://doi.org/10.1182/blood.V122.21.485.485

Published: 2013

Journal Articles

Results of the Phase 1 Trial of RG7112, a Small-Molecule MDM2 Antagonist, in Acute Leukemia

Blood (2012) 120 (21): 675.

https://doi.org/10.1182/blood.V120.21.675.675

Published: 2012

NARROW

Staphylococcus Species Leads the Eskape Infections in Various Hematological Malignancies

Leukapheresis Reduces 4-Week Mortality in Leukemia Patient with Hyperleukocytosis-a Retrospective Study from a Tertiary Center

Systematic Drug Repositioning By Integrating Transcriptome and Historical Clinical Data, Identification of Digoxin As a Novel Drug Reposition Candidate for High-Risk Myelodysplastic Syndromes

Mechanistic Role of HEXIM1 Induction in BRD4-Antagonist Mediated Growth Inhibition, Differentiation and in Vivo Lethal Activity Against Human AML Blast Progenitor Cells

Combined Targeting of β-Catenin and FLT-3 Is Synergistically Lethal Against Cultured and Primary AML Blast Progenitor Cells Expressing FLT3 Internal Tandem Duplication (ITD)

Neighborhood Death Rate: A Big-Data Based Health Informatics Pipeline Helps Identify Factors Impacting Clinical Outcomes and Cost Effectiveness in Acute Myeloid Leukemia Patients

Romidepsin Induces Durable Responses in Patients with Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL)

Superior Pre-Clinical Activity of BET (Bromodomain and Extra terminal) Protein Antagonist Combined with Ibrutinib, Panobinostat or Carfilzomib Against Human Mantle Cell Lymphoma (MCL) Cells

Combined Therapy With BRD4 Antagonist and JAK Inhibitor Is Synergistically Lethal Against Human Myeloproliferative Neoplasm (MPN) Cells

A Retrospective Review Of Factor X Levels and Bleeding Risk In Patients With Amyloidosis

Phase 1 Study Of Investigational Agent MLN8237 (Alisertib) + Rituximab ± Vincristine In Patients (Pts) With Relapsed/Refractory (Rel/Ref) Aggressive B-Cell Lymphomas

Combined Therapy With BRD4 Antagonist and FLT3 Inhibitor Exerts Synergistic Activity Against Cultured and Primary AML Blast Progenitors Expressing FLT-ITD

BRD4 Antagonist and Histone Deacetylase Inhibitor: A Novel Synergistic Combination Against Human Acute Myeloid Leukemia (AML) Cells

Results of the Phase 1 Trial of RG7112, a Small-Molecule MDM2 Antagonist, in Acute Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only